Read about the different classes of the World Health Organization's (WHO) Pulmonary Hypertension Functional Classification.| Pulmonary Hypertension News
Three months of CS1 therapy boosted quality of life, while symptoms tied to heart failure and clinical worsening and mortality risk declined.| Pulmonary Hypertension News
The U.S. FDA has granted orphan drug designation to CS1, Cereno Scientific’s lead therapy candidate for treating pulmonary arterial hypertension (PAH).| Pulmonary Hypertension News
Cereno's expanded access program for investigational therapy CS1 covers 10 PAH patients, following a Phase 2a clinical trial.| Pulmonary Hypertension News
The investigational therapy CS1 led to beneficial changes in for people with pulmonary arterial hypertension in a Phase 2a clinical trial.| Pulmonary Hypertension News
The FDA has approved the use of Cereno Scientific’s CS1 in an extension of the ongoing Phase 2 trial testing the therapy in people with PAH.| Pulmonary Hypertension News
Study record managers: refer to the Data Element Definitions if submitting registration or results information.| clinicaltrials.gov
Sitemap| Cereno Scientific
CS1-003 is a Phase IIa trial evaluating the safety, tolerability, pharmacokinetics, and exploratory efficacy of CS1 on top of standard-of-care in patients with PAH. The study, which was performed at 10 clinical sites in the US, randomized 25 patients to CS1 treatment, | Cereno Scientific
Pulmonary arterial hypertension (PAH) is a rare type of pulmonary hypertension that can be the result of one of several causes, or by no apparent cause. Read more information about PAH here.| Pulmonary Hypertension News
Category archive page for News.| Pulmonary Hypertension News